Despite its potential, navitoclax faces several challenges. The primary issue is its toxicity, particularly its impact on platelet counts, which limits its use. Additionally, resistance mechanisms can develop in tumor cells, reducing the drug's effectiveness over time. Ongoing research aims to overcome these challenges through combination therapies and the development of novel formulations.
